The ability of immune cells—particularly CD8+ T cells—to launch a rapid burst of proliferation inside tumors is key to the success of modern day cancer immunotherapies. However, the factors and mechanisms that drive this burst in proliferation remain p…
KEYMAKER-U03 is an international, multicenter, open-label, Phase I/II umbrella trial evaluating experimental combinations of pembrolizumab-based immunotherapy and targeted treatments for advanced clear cell renal cell carcinoma (ccRCC).
A novel combination therapy pairing a DNA-synthesis inhibitor with a targeted radiopharmaceutical may improve outcomes for patients with advanced neuroendocrine tumors, according to new clinical trial data presented at the European Society for Medical …
Researchers from the Alliance for Clinical Trials in Oncology have found that two targeted immunotherapy drugs lead to high remission rates and long survival with reasonable side effects for older patients with a tough-to-treat form of leukemia.
A new study led by UCLA investigators found that combining zanzalintinib, a targeted therapy drug, and atezolizumab, an immune checkpoint inhibitor, helped patients with metastatic colorectal cancer, the second most common cause of cancer death in the …
Patients with muscle-invasive bladder cancer who test positive for circulating tumor (ct)DNA after surgery to remove the cancer benefit from immunotherapy with atezolizumab compared to placebo whereas ctDNA-negative patients may potentially be spared u…
In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents—antibody-drug conjugates (ADCs)—can dramatically improve outcomes for patients with early-stage HER2-positive breas…
Working with an international team of collaborators, scientists at Columbia University have found a way to shift the balance of a type of white blood cell inside a stomach tumor, causing the immune system to recognize and attack the cancer instead of i…
Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody drug conjugate sacituzumab govitecan compared to sta…
A multicenter Phase II clinical trial led by researchers at The University of Texas MD Anderson Cancer Center demonstrated significant tumor shrinkage and disease control in patients with advanced pheochromocytoma and paraganglioma (PPGL), two rare and…
